A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Stapuldencel-T (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms VIABLE
- Sponsors SOTIO
- 10 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 24 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.